Brii Biosciences Limited (HKG:2137)

Market Cap	1.13B +37.0%
Revenue (ttm)	31.53M -24.2%
Net Income	-411.68M
EPS	-0.57
Shares Out	721.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,064,000
Average Volume	1,240,900
Open	1.490
Previous Close	1.490
Day's Range	1.460 - 1.580
52-Week Range	1.080 - 3.090
Beta	1.34
RSI	53.39
Earnings Date	Mar 20, 2026

About Brii Biosciences

Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 96
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2137

Financial Performance

In 2024, Brii Biosciences's revenue was 49.94 million, a decrease of -10.65% compared to the previous year's 55.89 million. Losses were -508.16 million, 190.7% more than in 2023.

Financial numbers in CNY